Advertisement
Advertisement

PBYI

PBYI logo

PUMA BIOTECHNOLOGY INC

8.91
USD
Sponsored
+0.79
+9.73%
Aug 07, 15:59 UTC -4
Closed
exchange

After-Market

8.82

-0.09
-1.05%

PUMA BIOTECHNOLOGY INC Profile

About

Puma Biotechnology, Inc. is a small cancer biotech whose only marketed product, Nerlynx (neratinib) was launched in the United Statesfor the treatment of early stage HER2-positive breast cancer in patients who have been previously treated with Roche's Herceptin-based adjuvant therapy. The drug was also approved in the European Union. Nerlynx in combination with Roche's Xeloda was approved?by the Food and Drug Administration for third-line HER2-positive metastatic breast cancer. Meanwhile, several additional studies on Nerlynx targeting different types of breast cancer patient populations as well as other types of cancers are currently underway. A key analysis of Nerlynx is the phase II SUMMIT basket study for treating solid tumors in patients with activating EGFR, HER2 or HER4 mutated cancers. Puma markets Nerlynx in the United States and has several sub-licenses in various regions outside the United States to commercialize Nerlynx in some international markets.

Info & Links

CEO

Alan H. Auerbach

Headquarters

10880 WILSHIRE BOULEVARD, SUITE 1700
LOS ANGELES, CA 90024, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.pumabiotechnology.com

Auditor

KPMG LLP

Share holders

9

Employees

179

PUMA BIOTECHNOLOGY INC Statistics

Valuation Measures

Market Capitalization2

448.73M

Enterprise Value

412.19M

Enterprise Value/EBITDA(ttm)

10.07

Price to Earnings Ratio(ttm)

17.13

Price to Sales(ttm)

1.96

Price to Book(mrq)

3.53

Price to Cash(ytd)

10.68

Profitability

Gross Margin(ttm)

75.42%

Operating Margin(ttm)

11.50%

Profit Margin(ttm)

10.04%

Return on Equity(ttm)

21.34%

Return on Invested Capital(ttm)

20.97%

Return on Assets(ttm)

13.04%

Income Statement

Revenue(ttm)

231.24M

Revenue Per Share(ttm)

4.48

Gross Profit(ttm)

173.04M

EBITDA(ttm)3

40.92M

Net Income Available to Common(ttm)

26.72M

Diluted EPS(ttm)

0.52

Share Statistics

Beta (5Y Monthly)

1.22

52-Week Change

170.82%

S&P 500 52-Week Change

21.72%

S&P 500 Member

No

Stock Optionable

Yes

Total Shares Outstanding1

51.62M

Dividend Yield

0.00%

Float4

39.60M

% Held by Insiders

22.20%

% Held by Institutions

61.29%

Balance Sheet

Total Cash(mrq)

93.90M

Total Cash Per Share(mrq)

1.82

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

2.91%

Quick Ratio(mrq)

2.24%

Book Value Per Share(mrq)

2.71

Cash Flow

Operating Cash Flow Per Share(ytd)

0.32

Free Cash Flow(ytd)

17.04M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement